The effect of Maraviroc on gut and immune function in HIV+ patients

• Research type

  Research Study

• Full title

  Investigating the effect of Maraviroc on microbial translocation in HIV-1 infected individuals who are receiving antiretroviral therapy.

• IRAS ID

  93959

• Contact name

  Ranjababu Kulasegaram

• Sponsor organisation

  Guy's & St Thomas' NHS Foundation Trust

• Eudract number

  2010-023625-38

• ISRCTN Number

  ISRCTN81045654

• Research summary

  This is a proof of concept study in which 10 HIV positive individuals on antiretroviral therapy (ART) with a CD4 count <500 will receive an extra HIV drug called Maraviroc for 6 months. Blood tests will be carried out at 4 time points and individuals will have a bowel biopsy at the beginning and end of the study. Blood and bowel samples will be analysed for changes in immune function, immune activation and the size of the HIV reservoir, all of which are markers of HIV disease progression. Patients will complete memory questionnaires to investigate whether an improvement in gut function can improve brain function as has been observed in liver disease. The results of the study will be made available to patients and will form the basis of a large scale clinical trial if results look promising.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  12/LO/0374

• Date of REC Opinion

  13 Nov 2012

• REC opinion

  Further Information Favourable Opinion